Richard Paulson compensation by year
Karyopharm Therapeutics Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $468,365 | $696,800 | $740,000 | $769,600 | $770,000 |
| Bonus | $300,000 | $200,000 | $200,000 | $0 | $100,100 |
| Stock awards | $3,523,008 | $2,982,788 | $1,201,200 | $854,604 | $838,996 |
| Option awards | $3,563,575 | $2,562,984 | $0 | $0 | $241,544 |
| Non-equity incentive | $435,500 | $452,920 | $456,950 | $425,425 | $350,350 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $64,724 | $14,523 | $28,138 | $19,712 | $19,912 |
| Total | $8,355,172 | $6,910,015 | $2,626,288 | $2,069,341 | $2,320,902 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karyopharm Therapeutics Inc. DEF 14A filed April 13, 2026, accession 0001503802-26-000023, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Karyopharm Therapeutics Inc. filed document, accession 0001503802-26-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 114,285 | $841,138 | — |
| RSU | 20,000 | $147,200 | — |
| RSU | 19,680 | $144,845 | — |
| PSU | 14,760 | $108,634 | — |
| RSU | 5,600 | $41,216 | — |
| PSU | 5,600 | $41,216 | — |
| RSU | 4,812 | $35,416 | — |
| Option | 999 | — | $154.95 |
| Option | 40,000 | — | $7.95 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Karyopharm Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 13, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-14 | Sale | — | 2,203 | $9.50 | 269,747 |
| 2026-05-13 | Grant or award | — | 4,920 | $0.00 | 271,950 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Karyopharm Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Paulson · this page | President and Chief Executive Officer | $2,320,902 |
| Reshma Rangwala | Executive Vice President, Chief Medical Officer and Head of Research | $2,016,134 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,399,580 |
Board service
Karyopharm Therapeutics board · FY2024–FY2025How this board is paid
Company policy: Karyopharm Therapeutics pays directors a $50,000 cash retainer and $15,142 in Options. As stated in Karyopharm Therapeutics's FY2025 proxy.
The full Karyopharm Therapeutics compensation record
free company briefThis page is one person within Karyopharm Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Karyopharm Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Karyopharm Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Karyopharm Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order KPTI
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.